Ann: Webcast Today - New Data from bioMUSE Natural History Study, page-65

Hi Domy,

I'm as impressed with the speech as you are.

During my walk today, I just cant find the justification for the current self off of the SP. The only thought I have is that the mid point release is post tax time, therefore investors can claim losses, AND/OR investors dont understand or see the positives from this studies potential new endpoint.

By including the improved imaging that can monitor the nigria so much better, it will be able to provide examples of: How sensitive the nigria is to excess iron, the speed of which the nigria atrophies, and how ATH434 works in this part of brain.

Therefore, the team will now be able to show a raft of new measures, such as ATH434 is working by slowing the atrophy progression/halting the disease process/, or actually reversing the atrophy and showing improvement of the disease (absolute god send if there were improvement and complete reversal).

As Dr Stamler stated, this new end point if added, and approved to be added, will assist get this drug to market.